-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
*The professional part involved in this article is only for medical professionals to read for reference.
Double insulin is included in medical insurance.
Innovative hypoglycemic drugs are more affordable! Tomorrow, March 1, the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2020)" (hereinafter referred to as the "2020 Drug Catalog") will be officially implemented! Since then, a large number of innovative drugs will be more affordable after medical insurance reimbursement, and patients will have more and better choices.
So what are the "gospels" for diabetics? 01The world's first soluble double insulin entered medical insurance! The "Drug List 2020" has negotiated to add 5 new diabetes drugs, including 1 insulin, 3 glucagon-like peptide-1 (GLP-1) receptor agonists and 1 sodium-glucose cotransporter 2 (SGLT-2) inhibitor [1].
The only insulin injection newly admitted is degluaspartin di-insulin, the world’s first soluble di-insulin (Figure 1), used to treat patients with type 2 diabetes (T2DM) that are difficult to control with other insulin or oral medications (OADs) .
The drug was launched in China in 2019 and has been widely used clinically.
Starting from March 1 this year, it will be officially included in the scope of medical insurance reimbursement, benefiting more diabetic patients.
Figure 1.
Deglustatin can be administered alone, combined with oral antidiabetic drugs, or combined with mealtime insulin [2], which can help patients in a variety of ways.
In terms of time, Degu aspartic insulin has not been on the market for a long time in China, so why can it be welcomed by clinicians and enter the medical insurance smoothly? 02Innovative preparations that better balance the effectiveness and safety of degludec Di-Insulin contains two components, the long-acting basic insulin analogue-insulin degludec, and the fast-acting insulin analogue-insulin aspart.
It is worth mentioning that the preparation has achieved an important breakthrough, that is, the two components can exist independently in the preparation and after injection, without interfering with each other [3], and 1-2 injections per day can take care of both fasting and meals.
After blood sugar control, it is possible to optimize the insulin treatment plan.
For patients whose blood glucose is still poorly controlled after taking OADs, degluaspartin can be used as the initial insulin treatment plan, taking into account both effectiveness and safety.
The initiation of Degu aspartic double insulin therapy can use a once-daily (QD) regimen.
A phase 3 clinical trial from Japan enrolled 296 T2DM patients with poorly controlled OADs (≥1 fixed-dose oral hypoglycemic drugs and poorly controlled blood sugar).
After a 26-week study, it was found that Compared with the insulin glargine QD regimen, the Degu aspartic double insulin QD regimen can significantly reduce the glycated hemoglobin (HbA1c) of patients (P<0.
01), and does not increase the risk of confirmatory hypoglycemia and confirmatory hypoglycemia at night (P=NS) In addition, the proportion of patients with HbA1c<7% and no confirmed hypoglycemia in the Degu aspart insulin group was higher (43% vs.
25%; P<0.
01) [4].
For patients with hyperglycemia after multiple meals, degu aspart di-insulin can be initiated twice a day (BID) regimen.
A 26-week open-label, two-group randomized, parallel controlled trial, involving a total of 394 patients with type 2 diabetes who have not used insulin before (two oral medications for patients with poor blood sugar control).
The effectiveness and safety of dual insulin BID and insulin aspart 30 BID treatment regimens.
The study found that the HbA1c control status of the two groups of patients was similar.
However, the fasting blood glucose (FPG) decreased more significantly in the patients who used Degu aspartate insulin (-4.
3 mmol/L vs.
-3.
3 mmol/L), and the overall confirmation was Compared with the control group, the risk of hypoglycemia event was reduced by 54% (P<0.
01); the risk of nocturnal hypoglycemia event was reduced by 75% (P<0.
01) [5].
In addition, Degu aspart insulin can also be used as one of the options for intensive insulin treatment.
A 38-week, international, open-label, randomized, treatment compliance trial involving 532 patients with T2DM who used basal insulin in combination with or without oral hypoglycemic drugs and required intensive insulin therapy, compared with the use of Degu aspartame Efficacy and safety of double insulin QD/BID and insulin glargine QD+insulin aspart 1-3 injections.
Compared with insulin glargine QD+1-3 injections of insulin aspart treatment plan, degluaspart double insulin QD/BID plan achieves similar HbA1c control with fewer injections, and has similar changes in fasting blood glucose and postprandial SMBG increase.
, Significantly reduce the risk of night hypoglycemia and reduce the total daily dose of insulin [6].
If the patient has already used other insulin treatment options, it can also be converted to degluaspart insulin.
In a prospective observational study, patients with T2DM who had previously been treated with premixed human insulin or premixed insulin analogues were enrolled.
They continued the treatment for 2 months and switched to BID therapy with Degol Aspartic insulin and observed two conversion treatments.
Improvement of efficacy, safety and quality of life at month.
The results showed that premixed insulin was converted to degluaspartin, before/after breakfast and dinner, and before/after breakfast and dinner, and the average blood sugar was significantly reduced, and the patient's quality of life was improved.
Subgroup analysis of previous use of premixed human insulin showed that when premixed human insulin was converted to degluaspart, the average blood glucose was significantly reduced (P=0.
047) (Figure 2) [7].
Figure 2.
The average blood glucose level of patients who used premixed human insulin before converted to degluaspartin was significantly reduced after the implementation of 03 medical insurance catalogue, the health and economic benefits of double insulin were further improved.
Based on the previous research literature, degluaspartin is entering Before the National Medical Insurance Catalogue, an economic evaluation has been carried out and a report has been published.
The results show that whether it is used for T2DM patients whose oral medication is difficult to control, or other T2DM patients whose insulin is difficult to control, compared with the reference drug regimen (Insulin Glargine regimen) , Basic-meal insulin and other programs), Degu aspartic acid can improve the quality of life of patients and save medical costs, which is a cost-saving treatment option [8-10]. With the smooth conclusion of the national medical insurance negotiations in 2020, Degu asparto insulin is included in the national medical insurance catalog at a more affordable price, and the cost of hypoglycemic treatment is further reduced, which will also bring more health and economic benefits to China's T2DM prevention and treatment.
Provide more ideal and economical insulin treatment options.
Summary Tomorrow, with the official implementation of the "2020 Drug Catalog", more hypoglycemic drugs will become more beneficial to the people.
Among them, Degu aspart insulin has entered the Chinese market for more than a year.
Whether it is used as an initial insulin treatment or intensive treatment, or converted from other insulin treatments to degu aspart insulin therapy, it can take into account the effect of hypoglycemic effect.
Sexuality and safety can also help patients reduce treatment costs.
It has actually helped some T2DM patients.
Now it is included in the medical insurance drug catalog.
I hope that more T2DM patients will benefit from this! References: [1].
"National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2020)" [2].
Degu Aspart Dual Insulin Instructions[3.
Havelund, et al.
Pharm Res.
2015;32 :2250–8[4].
Onishi Y, et al.
Diabetes Obes Metab.
2013;15:826–832.
[5].
Franek E, et al.
Diabet Med.
2016;33(4):497-505.
[6].
Philis-Tsimikas A, et al.
Diabetes Research and Clinical Practice.
2019;147:157-165.
[7].
Fujimoto K, et al.
Diabetol Metab Syndr.
2018;10:64.
[8].
Wang Fangxu, et al.
Chinese Pharmaceutical Economics.
2020;15(7):24-30.
[9].
Zhou L, et al.
Value in Health Regional Issues, 2020, 22:S33, PDB8.
[10].
Zhou L , et al.
Value in Health Regional Issues, 2020, 22:S33-S34, PDB12.
Double insulin is included in medical insurance.
Innovative hypoglycemic drugs are more affordable! Tomorrow, March 1, the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2020)" (hereinafter referred to as the "2020 Drug Catalog") will be officially implemented! Since then, a large number of innovative drugs will be more affordable after medical insurance reimbursement, and patients will have more and better choices.
So what are the "gospels" for diabetics? 01The world's first soluble double insulin entered medical insurance! The "Drug List 2020" has negotiated to add 5 new diabetes drugs, including 1 insulin, 3 glucagon-like peptide-1 (GLP-1) receptor agonists and 1 sodium-glucose cotransporter 2 (SGLT-2) inhibitor [1].
The only insulin injection newly admitted is degluaspartin di-insulin, the world’s first soluble di-insulin (Figure 1), used to treat patients with type 2 diabetes (T2DM) that are difficult to control with other insulin or oral medications (OADs) .
The drug was launched in China in 2019 and has been widely used clinically.
Starting from March 1 this year, it will be officially included in the scope of medical insurance reimbursement, benefiting more diabetic patients.
Figure 1.
Deglustatin can be administered alone, combined with oral antidiabetic drugs, or combined with mealtime insulin [2], which can help patients in a variety of ways.
In terms of time, Degu aspartic insulin has not been on the market for a long time in China, so why can it be welcomed by clinicians and enter the medical insurance smoothly? 02Innovative preparations that better balance the effectiveness and safety of degludec Di-Insulin contains two components, the long-acting basic insulin analogue-insulin degludec, and the fast-acting insulin analogue-insulin aspart.
It is worth mentioning that the preparation has achieved an important breakthrough, that is, the two components can exist independently in the preparation and after injection, without interfering with each other [3], and 1-2 injections per day can take care of both fasting and meals.
After blood sugar control, it is possible to optimize the insulin treatment plan.
For patients whose blood glucose is still poorly controlled after taking OADs, degluaspartin can be used as the initial insulin treatment plan, taking into account both effectiveness and safety.
The initiation of Degu aspartic double insulin therapy can use a once-daily (QD) regimen.
A phase 3 clinical trial from Japan enrolled 296 T2DM patients with poorly controlled OADs (≥1 fixed-dose oral hypoglycemic drugs and poorly controlled blood sugar).
After a 26-week study, it was found that Compared with the insulin glargine QD regimen, the Degu aspartic double insulin QD regimen can significantly reduce the glycated hemoglobin (HbA1c) of patients (P<0.
01), and does not increase the risk of confirmatory hypoglycemia and confirmatory hypoglycemia at night (P=NS) In addition, the proportion of patients with HbA1c<7% and no confirmed hypoglycemia in the Degu aspart insulin group was higher (43% vs.
25%; P<0.
01) [4].
For patients with hyperglycemia after multiple meals, degu aspart di-insulin can be initiated twice a day (BID) regimen.
A 26-week open-label, two-group randomized, parallel controlled trial, involving a total of 394 patients with type 2 diabetes who have not used insulin before (two oral medications for patients with poor blood sugar control).
The effectiveness and safety of dual insulin BID and insulin aspart 30 BID treatment regimens.
The study found that the HbA1c control status of the two groups of patients was similar.
However, the fasting blood glucose (FPG) decreased more significantly in the patients who used Degu aspartate insulin (-4.
3 mmol/L vs.
-3.
3 mmol/L), and the overall confirmation was Compared with the control group, the risk of hypoglycemia event was reduced by 54% (P<0.
01); the risk of nocturnal hypoglycemia event was reduced by 75% (P<0.
01) [5].
In addition, Degu aspart insulin can also be used as one of the options for intensive insulin treatment.
A 38-week, international, open-label, randomized, treatment compliance trial involving 532 patients with T2DM who used basal insulin in combination with or without oral hypoglycemic drugs and required intensive insulin therapy, compared with the use of Degu aspartame Efficacy and safety of double insulin QD/BID and insulin glargine QD+insulin aspart 1-3 injections.
Compared with insulin glargine QD+1-3 injections of insulin aspart treatment plan, degluaspart double insulin QD/BID plan achieves similar HbA1c control with fewer injections, and has similar changes in fasting blood glucose and postprandial SMBG increase.
, Significantly reduce the risk of night hypoglycemia and reduce the total daily dose of insulin [6].
If the patient has already used other insulin treatment options, it can also be converted to degluaspart insulin.
In a prospective observational study, patients with T2DM who had previously been treated with premixed human insulin or premixed insulin analogues were enrolled.
They continued the treatment for 2 months and switched to BID therapy with Degol Aspartic insulin and observed two conversion treatments.
Improvement of efficacy, safety and quality of life at month.
The results showed that premixed insulin was converted to degluaspartin, before/after breakfast and dinner, and before/after breakfast and dinner, and the average blood sugar was significantly reduced, and the patient's quality of life was improved.
Subgroup analysis of previous use of premixed human insulin showed that when premixed human insulin was converted to degluaspart, the average blood glucose was significantly reduced (P=0.
047) (Figure 2) [7].
Figure 2.
The average blood glucose level of patients who used premixed human insulin before converted to degluaspartin was significantly reduced after the implementation of 03 medical insurance catalogue, the health and economic benefits of double insulin were further improved.
Based on the previous research literature, degluaspartin is entering Before the National Medical Insurance Catalogue, an economic evaluation has been carried out and a report has been published.
The results show that whether it is used for T2DM patients whose oral medication is difficult to control, or other T2DM patients whose insulin is difficult to control, compared with the reference drug regimen (Insulin Glargine regimen) , Basic-meal insulin and other programs), Degu aspartic acid can improve the quality of life of patients and save medical costs, which is a cost-saving treatment option [8-10]. With the smooth conclusion of the national medical insurance negotiations in 2020, Degu asparto insulin is included in the national medical insurance catalog at a more affordable price, and the cost of hypoglycemic treatment is further reduced, which will also bring more health and economic benefits to China's T2DM prevention and treatment.
Provide more ideal and economical insulin treatment options.
Summary Tomorrow, with the official implementation of the "2020 Drug Catalog", more hypoglycemic drugs will become more beneficial to the people.
Among them, Degu aspart insulin has entered the Chinese market for more than a year.
Whether it is used as an initial insulin treatment or intensive treatment, or converted from other insulin treatments to degu aspart insulin therapy, it can take into account the effect of hypoglycemic effect.
Sexuality and safety can also help patients reduce treatment costs.
It has actually helped some T2DM patients.
Now it is included in the medical insurance drug catalog.
I hope that more T2DM patients will benefit from this! References: [1].
"National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2020)" [2].
Degu Aspart Dual Insulin Instructions[3.
Havelund, et al.
Pharm Res.
2015;32 :2250–8[4].
Onishi Y, et al.
Diabetes Obes Metab.
2013;15:826–832.
[5].
Franek E, et al.
Diabet Med.
2016;33(4):497-505.
[6].
Philis-Tsimikas A, et al.
Diabetes Research and Clinical Practice.
2019;147:157-165.
[7].
Fujimoto K, et al.
Diabetol Metab Syndr.
2018;10:64.
[8].
Wang Fangxu, et al.
Chinese Pharmaceutical Economics.
2020;15(7):24-30.
[9].
Zhou L, et al.
Value in Health Regional Issues, 2020, 22:S33, PDB8.
[10].
Zhou L , et al.
Value in Health Regional Issues, 2020, 22:S33-S34, PDB12.
